Isatin come on the stage of CDK4/6 inhibitor
Abstract
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved the prognosis for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, including those with metastatic or advanced breast cancer (mBC/ABC). Recent research has focused on developing CDK4/6 inhibitors with diverse structural frameworks, including isatin-based compounds. Isatin and its derivatives have shown promise in inhibiting CDK4/6, with potential efficacy against breast cancer cell lines. Studies have also indicated that isatinyl-2-aminobenzoylhydrazone (ISABH) complexes, particularly those with transition metals like nickel (Ni-ISABH), exhibit strong binding affinities to CDK6 and fulfill key pharmacokinetic criteria.
References
Pandey, K., An, H.-J., Kim, S.K., Lee, S.A., Kim, S., Lim, S.M., Kim, G.M., Sohn, J. and Moon, Y.W. 2019. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International Journal of Cancer.2019;145(5):1179-1188. https://doi.org/10.1002/ijc.32020
Jhaveri, K., Burris Rd, H.A., Yap, T.A., Hamilton, E., Rugo, H.S., Goldman, J.W., Dann, S., Liu, F., Wong, G.Y., Krupka, H. and Shapiro, G.I. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy.2021.https://doi.org/10.1080/14737140.2021.1944109
Yousuf, M., Khan, P., Shamsi, A., Shahbaaz, M., Hasan, G.M., Haque, Q.M.R., Christoffels, A., Islam, A. and Hassan, M.I. 2020. Inhibiting CDK6 activity by quercetin is an attractive strategy for cancer therapy. ACS omega.2020;5(42): 27480-27491. https://doi.org/10.1021/acsomega.0c03975
Nusantoro, YR. and Fadlan, A. In silico studies of isatinyl-2-aminobenzoylhydrazone transition metal complexes against cyclin-dependent kinase 6 (CDK6). Pharmacy Reports, 2021;1(1):4. https://doi.org/10.51511/pr.4
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.